Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMD1 | P17707 | 9/20 | 0.76 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.64 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | NADK | O95544 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | GAPDH | P04406 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952454 | 1.00 | AMD1 (0.76) | AMD1HSPA5HSPA8RXFP1NADK | |
| SCHEMBL15906323 | 0.89 | HSPA8 (0.80) | AMD1HSPA5HSPA8RXFP1HSD17B10 | |
| SCHEMBL15906300 | 0.89 | HSPA8 (0.80) | AMD1HSPA5HSPA8RXFP1HSD17B10 | |
| SCHEMBL967122 | 0.89 | HSPA8 (0.80) | AMD1HSPA5HSPA8RXFP1HSD17B10 | |
| SCHEMBL1135195 | 0.89 | HSPA8 (0.80) | AMD1HSPA5HSPA8RXFP1HSD17B10 | |
| SCHEMBL18858928 | 0.89 | HSPA8 (0.80) | AMD1HSPA5HSPA8RXFP1HSD17B10 | |
| SCHEMBL967124 | 0.89 | HSPA8 (0.80) | AMD1HSPA5HSPA8RXFP1HSD17B10 | |
| SCHEMBL16378774 | 0.89 | AMD1 (0.77) | AMD1HSPA5HSPA8RXFP1NADK | |
| SCHEMBL16805420 | 0.89 | HSPA8 (0.80) | AMD1HSPA5HSPA8RXFP1HSD17B10 | |
| SCHEMBL12946772 | 0.88 | HSPA8 (0.64) | AMD1HSPA5HSPA8RXFP1NADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009354-A1 | 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | claimed |
| EP-2170057-A1 | 5'-SUBSTITUTED ADENOSYNES, PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | Southern Research Institute (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2009018541-A1 | 5'-SUBSTITUTED ADENOSYNES, PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | SOUTHERN RESEARCH INSTITUTE (US) | 2009-02-05 | — | — | WO | claimed |
| US-8637485-B2 | 5′,-substituted adenosynes preparation thereof and use as inhibitors of S-adenosylmethionine decarboxylase | SOUTHERN RESEARCH INSTITUTE (US) | 2014-01-28 | — | — | US | disclosed |
| US-8633168-B2 | Inhibitors of S-adenosyl-L-methionine decarboxylase | GENZYME CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633168-B2 | Inhibitors of S-adenosyl-L-methionine decarboxylase | GENZYME CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2574616-A2 | 5'-substituted adenosynes, preparation thereof and use as inhibitors of s-adenosylmethionine decarboxylase. | Southern Research Institute (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20110009354-A1 | 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| US-20100261668-A1 | INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE | GENZYME CORPORATION | 2010-10-14 | — | — | US | disclosed |
| US-20100261668-A1 | INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE | GENZYME CORPORATION | 2010-10-14 | — | — | US | disclosed |
| WO-2008157438-A1 | INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE | GENZYME CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009354-A1 | 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | AMD1, ADA, MTAP | AMD1 1/4885HSPA5 4806/4885HSPA8 2018/4885 |
| US-20100261668-A1 | INHIBITORS OF S-ADENOSYL-L-METHIONINE DECARBOXYLASE | AMD1, MAT1A, AHCY | AMD1 1/4885HSPA5 4426/4885HSPA8 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.